Stargardt Disease 1 Clinical Trial
Official title:
Phase 3, Multicenter, Randomized, Double-Masked, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Tinlarebant in the Treatment of Stargardt Disease in Adolescent Subjects
The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
Approximately 90 subjects will be enrolled in this study. Subjects will be assigned to study drug (tinlarebant 5 mg/placebo) with treatment period of upto 24 months with 28 days of follow-up. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04281732 -
Visual Performance Measures in a Virtual Reality Environment for Assessing Clinical Trial Outcomes in Those With Severely Reduced Vision
|
||
| Recruiting |
NCT05258032 -
Structural and Functional Characterization of Rare Ocular Diseases
|
||
| Active, not recruiting |
NCT06300476 -
Safety and Efficacy of a Single Subretinal Injection of JWK006 Gene Therapy in Subjects With Stargardt Disease(STGD1)
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05674058 -
Function and Imaging Assessments for G1961E-associated Stargardt Disease
|
||
| Completed |
NCT03297515 -
Therapeutic Potential of Omega-3 Fatty Acids Supplementation in Dry Macular Degeneration and Stargardt Disease
|
N/A | |
| Not yet recruiting |
NCT06388083 -
A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03364153 -
Zimura Compared to Sham in Patients With Autosomal Recessive Stargardt Disease (STGD1)
|
Phase 2 | |
| Enrolling by invitation |
NCT03772938 -
Stem Cells Therapy in Degenerative Diseases of the Retina
|
Phase 1 |